CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program-Reference-Cited by-同舟云学术

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program

Published:2019-04-01 Issue:2 Volume:38 Page:60-69
ISSN:2167-9436
Container-title:Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
language:en
Short-container-title:Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Author:

Thaventhiran Thilipan¹,Wong Wai¹,Alghanem Ahmad F.¹,Alhumeed Naif¹,Aljasir Mohammad A.¹,Ramsey Simeon²,Sethu Swaminathan¹,Aw Yeang Han Xian¹,Chadwick Amy E.¹,Cross Michael¹,Webb Steven D.¹,Djouhri Laiche³,Ball Christina⁴,Stebbings Richard⁴,Sathish Jean G.¹

Affiliation:

1. Medical Research Council Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.

2. Inflammation and Remodeling, Pfizer Research Unit, Cambridge, Massachusetts.

3. Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.

4. National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.

Publisher

Mary Ann Liebert Inc

Subject

Immunology,Immunology and Allergy

Link

https://www.liebertpub.com/doi/pdf/10.1089/mab.2018.0042

Reference50 articles.

1. Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08

2. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412